Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych TopicsAddiction psychiatry — substance use disorders

Psych · Addiction psychiatry — substance use disorders

Opioid use disorder

Also known as OUD · Opioid dependence · Heroin dependence · Opioid addiction · Narcotic dependence · Opioid agonist treatment · Medication for opioid use disorder · Methadone maintenance · Buprenorphine treatment

Fellowship reference on opioid use disorder: DSM-5 criteria, overdose recognition and naloxone, COWS, methadone, buprenorphine and naltrexone from the labels, QTc, detoxification, pregnancy, and the mortality evidence for retention in treatment. FRANZCP-primary, globally tagged.

high26 referencesUpdated 26 July 20269 min readSource-verified · Oct 2026

Checked against its sources on 23 Oct 2026

Practise this topic

  • 10 MCQs

Your progress

Saved on this device.

Practise this topic10 MCQs with explanations

Target exams

FRANZCPMRCPsychABPNMD-DNBNEET-SS

Red flags

  • In severe respiratory depression, restoration of ventilation and oxygenation takes precedence over the history, examination or diagnostic testing
  • Naloxone, with its transient duration of action, does not forestall recrudescent respiratory depression in many patients intoxicated with opioid analgesics
  • Methadone levels accumulate over the first several days, and deaths have occurred in early treatment due to the cumulative effects
  • Opioids with benzodiazepines or other CNS depressants, including alcohol, may cause profound sedation, respiratory depression, coma and death
  • The time immediately after leaving opioid substitution treatment is a period of particularly increased mortality risk
On this page
Study tools

Your progress

Saved on this device.

Practise this topic10 MCQs with explanations

Target exams

FRANZCPMRCPsychABPNMD-DNBNEET-SS

Red flags

  • In severe respiratory depression, restoration of ventilation and oxygenation takes precedence over the history, examination or diagnostic testing
  • Naloxone, with its transient duration of action, does not forestall recrudescent respiratory depression in many patients intoxicated with opioid analgesics
  • Methadone levels accumulate over the first several days, and deaths have occurred in early treatment due to the cumulative effects
  • Opioids with benzodiazepines or other CNS depressants, including alcohol, may cause profound sedation, respiratory depression, coma and death
  • The time immediately after leaving opioid substitution treatment is a period of particularly increased mortality risk
One-line fellowship answer

Opioid agonist treatment can be highly effective in reducing illicit opioid use and improving multiple health and social outcomes, including by reducing overall mortality and deaths from overdose, suicide, HIV, hepatitis C and other injuries.[20] Retention in methadone or buprenorphine treatment is associated with substantial reductions in all-cause and overdose mortality, and the time immediately after leaving treatment is a period of particularly increased mortality risk.[4]

Meet the patient

A 29-year-old man is found slumped in a fast-food toilet, breathing slowly, with pinpoint pupils. Paramedics give naloxone; he wakes, swears, and refuses to stay. Four hours later on the ward he is drowsy again.

Why the examiner cares. Naloxone, with its transient duration of action, does not truncate opioid toxicity; in many patients intoxicated with opioid analgesics it does not forestall recrudescent respiratory depression.[10] After a non-fatal overdose, methadone maintenance (adjusted HR 0.47) and buprenorphine (adjusted HR 0.63) were associated with decreased all-cause mortality, yet only a minority of survivors received medication for OUD.[17]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References26ShowHide
  1. [1]Mattick RP, Breen C, Kimber J, Davoli M Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence Cochrane Database Syst Rev, 2009.PMID 19588333
  2. [2]Mattick RP, Breen C, Kimber J, Davoli M Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence Cochrane Database Syst Rev, 2014.PMID 24500948
  3. [3]Wesson DR, Ling W The Clinical Opiate Withdrawal Scale (COWS) J Psychoactive Drugs, 2003.PMID 12924748
  4. [4]Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies BMJ, 2017.PMID 28446428
  5. [5]Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial Lancet, 2018.PMID 29150198
  6. [6]D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial JAMA, 2015.PMID 25919527
  7. [7]Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure N Engl J Med, 2010.PMID 21142534
  8. [8]Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone N Engl J Med, 2003.PMID 12954743
  9. [9]Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial Arch Gen Psychiatry, 2011.PMID 22065255
  10. [10]Boyer EW Management of opioid analgesic overdose N Engl J Med, 2012.PMID 22784117
  11. [12]Strang J, Bird SM, Parmar MK Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial J Urban Health, 2013.PMID 23633090
  12. [13]Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved Drug Alcohol Depend, 2009.PMID 19608355
  13. [15]Gowing L, Farrell M, Ali R, White JM Alpha₂-adrenergic agonists for the management of opioid withdrawal Cochrane Database Syst Rev, 2016.PMID 27140827
  14. [16]Minozzi S, Amato L, Jahanfar S, Bellisario C, Ferri M, Davoli M Maintenance agonist treatments for opiate-dependent pregnant women Cochrane Database Syst Rev, 2020.PMID 33165953
  15. [17]Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study Ann Intern Med, 2018.PMID 29913516
  16. [18]Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC QTc interval screening in methadone treatment Ann Intern Med, 2009.PMID 19153406
  17. [19]Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N Opioid agonist treatment for pharmaceutical opioid dependent people Cochrane Database Syst Rev, 2016.PMID 27157143
  18. [20]Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action Lancet, 2019.PMID 31657732
  19. [21]Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. The American journal of psychiatry, 2013.PMID 23903334
  20. [22]US National Library of Medicine DailyMed METHADONE HYDROCHLORIDE TABLET [AMERICAN HEALTH PACKAGING] DailyMed, 2026.Source
  21. [23]US National Library of Medicine DailyMed SUBOXONE (BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE) FILM, SOLUBLE [INDIVIOR INC.] DailyMed, 2026.Source
  22. [24]US National Library of Medicine DailyMed NALOXONE HYDROCHLORIDE INJECTION [DR. REDDY'S LABORATORIES, INC.] DailyMed, 2026.Source
  23. [25]US National Library of Medicine DailyMed VIVITROL (NALTREXONE) KIT [ALKERMES, INC.] DailyMed, 2026.Source
  24. [26]US National Library of Medicine DailyMed LUCEMYRA (LOFEXIDINE HYDROCHLORIDE) TABLET, FILM COATED [USWM, LLC] DailyMed, 2026.Source
  25. [27]National Institute for Health and Care Excellence Drug misuse in over 16s: opioid detoxification (CG52) NICE clinical guideline CG52, 2007.Source
  26. [28]National Institute for Health and Care Excellence Methadone and buprenorphine for the management of opioid dependence (TA114) NICE technology appraisal TA114, 2007.Source

Test yourself

Practise what you just read

  • 10 MCQs
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousOpioid substitution therapy and withdrawalAddiction psychiatry — substance use disordersNextPaediatric psychopharmacologyChild and adolescent psychiatry — psychopharmacology